U.S. Markets open in 58 mins
  • S&P Futures

    3,430.00
    +7.25 (+0.21%)
     
  • Dow Futures

    28,164.00
    +64.00 (+0.23%)
     
  • Nasdaq Futures

    11,656.75
    +6.50 (+0.06%)
     
  • Russell 2000 Futures

    1,619.40
    +8.10 (+0.50%)
     
  • Crude Oil

    40.68
    -0.15 (-0.37%)
     
  • Gold

    1,904.60
    -7.10 (-0.37%)
     
  • Silver

    24.63
    -0.07 (-0.28%)
     
  • EUR/USD

    1.1815
    +0.0042 (+0.3544%)
     
  • 10-Yr Bond

    0.7610
    0.0000 (0.00%)
     
  • Vix

    28.83
    +1.42 (+5.18%)
     
  • GBP/USD

    1.2915
    -0.0026 (-0.1989%)
     
  • USD/JPY

    105.7400
    +0.3100 (+0.2940%)
     
  • BTC-USD

    11,838.03
    +781.02 (+7.06%)
     
  • CMC Crypto 200

    238.72
    +5.05 (+2.16%)
     
  • FTSE 100

    5,891.79
    +7.14 (+0.12%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

Veeva CRM to Help Medis Deliver Customized Experience to HCPs

Zacks Equity Research
·3 mins read

Veeva Systems Inc.VEEV recently announced that Medis has shifted to multichannel Veeva Customer Relationship Management (CRM) in 15 countries across Central and Eastern Europe to implement its commercial strategy and drive more efficient interactions with healthcare professionals (HCPs).

Medis is a leading independent medical marketing company that is committed toward the commercialization of innovative pharmaceutical products, mainly focused on specialty drugs, medical equipment and self-care brands.

This development is expected to expand the global reach of Veeva’s portfolio of cloud-based offerings for the life sciences industry.

More on the Development

Medis was in need of a CRM solution to proficiently deploy its customers’ commercial and medical strategies with speed and compliance

Veeva CRM will be lending Medis teams a flexible solution that adapts to the unique go-to market strategies of every customer.

Veeva CRM offers Medis’ field teams advanced mobility, multichannel capabilities, and real-time insights to drive engagement with the right customer in the right channel at the right time. Henceforth, Medis’ field teams will be able to deliver compliant, customized experiences with efficiency to HCPs across various channels, including face-to-face, email and web.

For investors’ notice, as part of the multichannel Veeva CRM, Medis is also implementing  Veeva CLM, Veeva CRM Engage Meeting and Veeva CRM Approved Email.

Market Prospects

Per a report by MarketsandMarkets, the global cloud computing market size is expected to rise from $371.4 billion in 2020 to $832.1 billion by 2025, at a CAGR of 17.5%.

Recent Developments

This month, Veeva Systems announced that Switzerland-based Idorsia Pharmaceuticals has chosen Veeva Commercial Could to enable its digital field force in the United States, Japan and countries across Europe. Veeva Commercial Cloud will help Idorsia build the foundation for digital excellence through multichannel engagement, data, content and analytics.

Apart from this, Veeva Systems announced recently that AstraZeneca has selected Veeva Vault QMS and Veeva Vault QualityDocs to combine quality management and content on a single cloud platform. This development is expected to enhance Veeva Systems’ commitment toward strengthening its cloud-based software.

Price Performance

Shares of the Zacks Rank #3 (Hold) company have gained 101.4% compared with the industry’s growth of 93.1% in the past six months.

Key Picks

A few better-ranked stocks from the broader medical space include OPKO Health OPK, Surmodics SRDX and Merit Medical Systems MMSI.

OPKO Health’s long-term earnings-growth rate is estimated at 12%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Surmodics’ long-term earnings growth-rate is estimated at 10%. The company presently carries a Zacks Rank #2.

Merit Medical Systems’ long-term earnings-growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
 
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
 
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
 
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research